Company intelligence / Profile preview

Apeiron Therapeutics

Burlingame, California, United Statesapeiron-bio.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The company is developing biomarker-driven cancer therapeutics. They recently presented preclinical data on their PRMT5 inhibitor GTA182 at the AACR 2025 Annual Meeting (as of March 25, 2025)[1].

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

GTA182

3 more assets in the full pipeline.

Beyond the preview

Go deeper on Apeiron Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apeiron Therapeutics.